Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omega-3-acid ethyl esters + rosuvastatin
- Development stage
- Unknown
- Lead developer
- Kuhnil Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KI1107 is a fixed-dose combination of omega-3-acid ethyl esters and rosuvastatin calcium developed by Kuhnil Pharmaceutical. It is indicated for the treatment of patients with hypertriglyceridemia or mixed dyslipidemia whose lipid levels are not sufficiently controlled by statin monotherapy. The product, marketed as Rosuomega, utilizes a unique tablet-in-capsule technology where rosuvastatin tablets are encapsulated within a soft gel capsule containing omega-3-acid ethyl esters. Rosuvastatin functions as an HMG-CoA reductase inhibitor to lower LDL cholesterol, while the omega-3 fatty acids (EPA and DHA) act as PPAR-alpha agonists to reduce hepatic triglyceride synthesis and enhance clearance. This combination provides a synergistic approach to managing complex lipid profiles by targeting both cholesterol and triglyceride pathways.
- Brand names
- Rosuomega
- Other names
- Omega-3 + Rosuvastatin
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on omega-3-acid ethyl esters + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omega-3-acid ethyl esters + rosuvastatin.